Skip to Content
Merck
All Photos(1)

Key Documents

SML2257

Sigma-Aldrich

IBR2

≥98% (HPLC)

Synonym(s):

(1R)-1,2-Dihydro-1-(1H-indol-3-yl)-2-[(phenylmethyl)sulfonyl]isoquinoline, (R)-2-(benzylsulfonyl)-1-(1H-indol-3-yl)-1,2-dihydroisoquinoline, Isoquinoline, 1,2-dihydro-1-(1H-indol-3-yl)-2-[(phenylmethyl)sulfonyl]-, (1R)-

Sign Into View Organizational & Contract Pricing


About This Item

Empirical Formula (Hill Notation):
C24H20N2O2S
CAS Number:
Molecular Weight:
400.49
UNSPSC Code:
12352200
NACRES:
NA.77

Assay

≥98% (HPLC)

form

powder

color

white to beige

solubility

DMSO: 2 mg/mL, clear

storage temp.

2-8°C

SMILES string

O=S(N1[C@@H](C2=CNC3=C2C=CC=C3)C4=CC=CC=C4C=C1)(CC5=CC=CC=C5)=O

Biochem/physiol Actions

IBR2 is a cell penetrant, potent and specific RAD51 inhibitor that inhibits RAD51-mediated DNA double-strand break repair and enhances cytotoxicity of multiple anticancer agents with disparate biochemical targets including the Bcr-Abl inhibitor imatinib and multiple kinase inhibitor regorafenib. IBR2 disrupts RAD51 multimerization, accelerates proteasome-mediated RAD51 protein degradation, reduces ionizing radiation-induced RAD51 foci formation, inhibits cancer cell growth and induces apoptosis.

Storage Class Code

11 - Combustible Solids

WGK

WGK 3

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable


Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Jiewen Zhu et al.
EMBO molecular medicine, 5(3), 353-365 (2013-01-24)
RAD51 recombinase activity plays a critical role for cancer cell proliferation and survival, and often contributes to drug-resistance. Abnormally elevated RAD51 function and hyperactive homologous recombination (HR) rates have been found in a panel of cancers, including breast cancer and
Peter J Ferguson et al.
The Journal of pharmacology and experimental therapeutics, 364(1), 46-54 (2017-10-25)
Although cancer cell genetic instability contributes to characteristics that mediate tumorigenicity, it also contributes to the tumor-selective toxicity of some chemotherapy drugs. This synthetic lethality can be enhanced by inhibitors of DNA repair. To exploit this potential Achilles heel, we
Jiewen Zhu et al.
European journal of medicinal chemistry, 96, 196-208 (2015-04-16)
RAD51 recombinase plays a critical role for cancer cell proliferation and survival. Targeting RAD51 is therefore an attractive strategy for treating difficult-to-treat cancers, e.g. triple negative breast cancers which are often resistant to existing therapeutics. To this end, we have

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service